Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010

被引：98

作者：

Vellozzi, Claudia ^{[1
]}

Broder, Karen R. ^{[1
]}

Haber, Penina ^{[1
]}

Guh, Alice ^{[1
]}

Nguyen, Michael ^{[2
]}

Cano, Maria ^{[1
]}

Lewis, Paige ^{[1
]}

McNeil, Michael M. ^{[1
]}

Bryant, Marthe ^{[2
]}

Singleton, James ^{[3
]}

Martin, David ^{[2
]}

DeStefano, Frank ^{[1
]}

机构：

[1] Ctr Dis Control & Prevent, Immunizat Safety Off, Div Hlth Care Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA

[2] US FDA, Off Biostat & Epidemiol, Ctr Biol Evaluat & Res, Rockville, MD 20857 USA

[3] Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA

来源：

VACCINE | 2010年 / 28卷 / 45期

关键词：

H1N1; vaccines; Vaccine safety; Post-marketing surveillance; GUILLAIN-BARRE-SYNDROME; SAFETY; CHILDREN; IMMUNIZATION; INTUSSUSCEPTION; ASSOCIATION; ANAPHYLAXIS; ADULTS;

D O I：

10.1016/j.vaccine.2010.09.021

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The United States (US) influenza A (H1N1) 2009 monovalent (2009-H1N1) vaccination program began in October 2009. Reports to the vaccine adverse event reporting system (VAERS), a US spontaneous reporting system, were reviewed to identify potential rare events or unusual adverse event (AE) patterns after 2009-H1N1 vaccination. The adverse event profile after 2009-H1N1 vaccine in VAERS (similar to 10,000 reports) was consistent with that of seasonal influenza vaccines, although the reporting rate was higher after 2009-H1N1 than seasonal influenza vaccines, this may be, at least in part, a reflection of stimulated reporting. Death, Guillain-Barre syndrome and anaphylaxis reports after 2009-H1N1 vaccination were rare (each <2 per million doses administered). Published by Elsevier Ltd.

引用

页码：7248 / 7255

页数：8

共 45 条

[1]

*AAN, 2009, REP TOOLK GUILL BARR

[2]

Anthony Fauci.S., 2008, HARRISONS PRINCIPLES

[3] Risk of anaphylaxis after vaccination of children and adolescents [J].

Bohlke, K ;

Davis, RL ;

Marcy, SM ;

Braun, MM ;

DeStefano, F ;

Black, SB ;

Mullooly, JP ;

Thompson, RS .

PEDIATRICS, 2003, 112 (04) :815-820

[4]

*BRIGHT COLL, 2008, BRIGHT COLL DEF GUID

[5]

*CDCP, 2009, MORBIDITY MORTALITY, P1351

[6]

*CDCP, 2009, INFL A H1N1 2009 MON

[7] THE VACCINE-ADVERSE-EVENT-REPORTING-SYSTEM (VAERS) [J].

CHEN, RT ;

RASTOGI, SC ;

MULLEN, JR ;

HAYES, SW ;

COCHI, SL ;

DONLON, JA ;

WASSILAK, SG .

VACCINE, 1994, 12 (06) :542-550

[8]

Cortese Margaret M., 2009, Morbidity and Mortality Weekly Report, V58, P1

[9]

*DEP HLTH HUM SERV, VAERS FORM

[10] The Vaccine Safety Datalink project [J].

DeStefano, F .

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2001, 10 (05) :403-406

← 1 2 3 4 5 →